


For personal use only



# Genetic Signatures

2015 Full Year Results  
Investor Presentation

# Disclaimer

This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange Limited (“ASX”).

This presentation contains statements that involve estimates, risks and uncertainties. Although the Company believes these statements to be reasonable at this time, Genetic Signatures can give no guarantee that the expectations reflected in these statements will prove to be accurate. Actual results could differ materially from those expected for any of a multitude of risks including, but not limited to, those inherent in regulatory or market environments or more generally. In preparing this presentation, the Company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it.

The presentation is proprietary to Genetic Signatures and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction and does not and will not form part of any securities subscription, purchase or sale contract.

# Transforming Molecular Diagnostics

Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (*in vitro* diagnostics) industry with new technology in infection control.

Our primary focus is the development and supply of world leading diagnostic solutions to hospitals and pathology laboratories globally for rapid detection and treatment of infectious diseases.



# Corporate Summary

For personal use only

<b>Capital Structure</b>	
ASX Code	GSS
Shares on Issue	72.9m
Market Capitalisation	\$34m
Share Price (at market close 22 September, 2015)	\$0.49
Cash at June 30	\$5.46m

<b>Directors &amp; Chief Executive</b>	
Nick Samaras	Non-Executive Chairman
John Melki	Director & CEO
Mike Aicher	Executive Director - US
Phillip Isaacs	Non-Executive Director
Pat Noland	Non-Executive Director
Tony Radford – appointed 15 <sup>th</sup> September 2015	Non-Executive Director

# 2015 Highlights

## Financial Growth

- Completed oversubscribed Initial Public Offering (IPO) to raise \$7.5 million and list on the Australian Securities Exchange (ASX)
- Achieved greater than \$1 million in annual sales revenue for the first time in the history of the Company
- Diagnostic kit sales revenue increase of 65% on prior year
- Australian hospitals and laboratories performed GSS' *EasyScreen*<sup>™</sup> tests more than 50,000 times in FY15
- First molecular diagnostic kits sales to a major national commercial pathology provider.
- First molecular diagnostic kit sales into Europe achieved
- Includes EU product revenue and continued sales growth of enteric product line in Australia

# 2015 Financial Results

For personal use only

	<b>30 June 2015</b> \$	<b>30 June 2014</b> \$	<b>% Increase (decrease)</b>
<b>Revenue from continuing operations</b>	1,043,269	684,277	52.5%
<b>Net loss from ordinary activities after tax attributable to shareholders</b>	(2,659,120)	(1,728,487)	(53.8)%
<b>Net loss for the period attributable to shareholders</b>	(2,659,120)	(1,728,487)	(53.8)%
<b>Losses per share (cents per share)</b>	(5.2)	(12.1)	57.0%
<b>Net tangible assets (cents per share)</b>	10.8	6.0	80.0%

# FY15 Results Overview

- 52.5% increase in operating revenue to \$1,043,269
- A number of significant non-recurring costs were paid in FY2015 and will not have any further impact on cash flow, including \$515,000 related to the Company's IPO and \$165,000 for capital equipment required to increase product development throughput in the R&D laboratory



For personal use only

# 2015 Operational Highlights

## Global Market Reach Expansion

- US subsidiary, Genetic Signatures US Ltd incorporated and its US team expanded
- Established first European sales channel partnerships with distributors for the regions of Italy and Israel

## Product Range Expansion

- Moved into new state of the art premises, allowing for increased product development
- Completed first domestic customer site installation of *EasyScreen*<sup>™</sup> Respiratory Virus Detection Kit for beta-testing
- First sales of *EasyScreen*<sup>™</sup> Respiratory Virus Detection Kit



# Genetic Signatures


## Transforming Global Molecular Diagnostics

For personal use only



# Company Overview

- Genetic Signatures provides diagnostic solutions for rapid pathogen detection
- Products already available in Australia and now launching into large global markets, worth **US\$1.11 billion** in 2012 growing to **US\$1.77 billion in 2017**
- Proprietary technology driving product development for pathology and hospital customers globally in multiple markets
- Experienced management team and board with track record in global molecular diagnostics industry




For personal use only

# Technology – 3Base™

***A transformational MDx technology enabling customers to identify a wider array of patient infections***

- Genetic Signatures 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subtypes
- Patent-protected chemical transformation of DNA and RNA sequences to reduce genetic code complexity
- Process can enhance detection of multiplexed assays where multiple targets are detected in the one tube
- Achieved by allowing a simpler design of molecular assays for the simultaneous detection of multiple targets

# EasyScreen™ Product Development Pathway




Each product goes through extensive development and beta testing and adheres to rigorous quality management systems & regulatory approach.

- ISO9001 and ISO13485 certified
- Already approved by Australian and European regulators

# Competitive Advantage

- GSS is unique in supplying products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format
- Uses latest technology compatible with existing equipment (open platform)
- Ease of use and automation
- Rapid time to result (<5hrs)
- High Volume laboratories accommodated
- Separate endogenous extraction and inhibition controls
- Viral, bacterial and protozoan coverage
- Cost effective kits supply
- Ongoing global support



For personal use only

# Global Growth Strategy



# FY16 Activities and Growth

- Expansion of *EasyScreen*<sup>™</sup> product range with anticipated commercial release of
  - New Respiratory panel that includes bacterial targets and increases throughput.
  - MRSA assay (otherwise known as 'Golden Staph')
  - Anticipated significant revenue increases from both the addition of new customers from various international markets and expansion of *EasyScreen*<sup>™</sup> product menu
- Increasing activity in Europe to support distributors and increase distributor network
- Anticipating first commercial sales in the USA

For personal use only

# Commercialisation Progress - Australia

- Currently in market with major hospital and pathology group customers
  - Testing for 22 causes of gastroenteritis
  - Testing for 15 causes of viral respiratory disease
  - Next new product in beta testing with customer
  - Dr Tony Radford joins Board of Directors

For personal use only




# Commercialisation Progress - Europe

- Established operations in 2013
- Signed Italian distributor and testing with large pathology laboratories, recurrent revenues commencing
- Signed Israeli distributor agreement
- Increased European sales channel partnership network by signing distribution agreements with partners for the regions of Poland and Ireland
- In discussions with distributors in other jurisdictions



## Commercialisation Progress - United States

- Established operations in 2014 with appointment of key personnel
- Anticipate entering market in 2015 In FY15 GSS achieved first regulatory step towards full product suite commercialisation in the US with receipt of a United States Food and Drug Administration (FDA) listing for a clinical sample concentrator. The FDA listing means that the Company can legally sell its *EasyScreen*<sup>™</sup> Sample Processing Kit in the US
- Appointment of Pat Noland, to head up Commercial Operations



# Summary

- *EasyScreen*<sup>™</sup> Respiratory & Enteric Pathogen Detection Kits provide **faster & more accurate screening** for viral, bacterial and protozoan pathogens – **tests are processed in hours instead of days**, with fewer false positives and negatives
- The 3Base<sup>™</sup> platform and products are protected by a **strong patent portfolio** - broad patent protecting the 3Base<sup>™</sup> technology platform until 2031
- Products already available in Australia with GSS having launched into global markets worth US\$1.11 billion in 2012 growing to **US\$1.77 billion in 2017**
- **Established operations in key global markets** of Europe and the US over the past year
- **Experienced management team and board** with track record in global molecular diagnostics industry

For personal use only

**Contact:**

**John Melki**  
**Chief Executive Officer**  
[john@geneticsignatures.com](mailto:john@geneticsignatures.com)

[www.geneticsignatures.com](http://www.geneticsignatures.com)